Cutaneous leishmaniasis - two cases, two perspectives

  • Inês Maio Pediatrics Department, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto
  • Carla Teixeira Pediatrics Department, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto
  • Catarina Prior Pediatrics Department, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto
  • Susana Machado Dermatology Department, Centro Hospitalar Universitário do Porto
  • Manuela Selores Dermatology Department, Centro Hospitalar Universitário do Porto
  • Laura Marques Pediatrics Department, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto
Keywords: intralesional treatment, leishmaniasis, old-world leishmaniasis, parasitic infections

Abstract

Although endemic in some regions, as the Douro river valley, cutaneous leishmaniasis is a rare zoonosis in Portugal. Children are the most affected age group. Treatment remains controversial, given the lack of scientific evidence.
The goal of cutaneous leishmaniasis treatment is to avoid dissemination and progression to disfiguring lesions.
The option between no, systemic, or intralesional treatment should be carefully assessed.

References

1. Cota GF, De Sousa MR, Fereguetti TO, Saleme PS, Alvarisa TK, Rabello A. The cure rate after placebo or no therapy in American cutaneous leishmaniasis: A systematic review and metaanalysis. PLoS One. 2016; 11:1–15.

2. World Health Organization. Surveillance of leishmaniasis in the WHO European Region, 2016 Leishmaniasis. WHO Wkly Epidemiol Rec. 2018; 40:521–30.


3. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the infectious diseases society of America (IDSA) and the American Society of tropical medicine and hygiene (ASTMH). Am J Trop Med Hyg. 2017; 96:24–45.

4. Showler AJ, Boggild AK. Cutaneous Leishmaniasis in Travellers: a Focus on Epidemiology and Treatment in 2015. Curr Infect Dis Rep. 2015; 17:489.

5. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. Elsevier B.V. 2011; 118:87–96.

6. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015; 16:237-52.

7. Uribe-Restrepo A, Cossio A, Desai MM, Dávalos D, Castro M del M. Interventions to treat cutaneous leishmaniasis in children: A systematic review. PLoS Negl Trop Dis. 2018; 12:e0006986.

8. Gradoni L, López-Vélez R, Mokni M. Manual on Case Management and Surveillance of the Leishmaniases in the WHO European Region. WHO Reg Off Eur. 2017.

9. Heras-Mosteiro J, Monge-Maillo B, Pinart M, Pereira PL, Garcia- Carrasco E, Cuadrado PC, et al. Interventions for Old World cutaneous leishmaniasis (Review). Cochrane Database Syst Rev. 2017. 12: CD005067.
Published
2019-07-18
Section
Case Reports